PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media289827ArticlesСтатьиResearch ArticleTHE ROLE OF PROBIOTICS IN THE TREATMENT OF HELICOBACTER PYLORI INFECTIONРОЛЬ ПРОБИОТИКОВ В ЛЕЧЕНИИ ХЕЛИКОБАКТЕРНОЙ ИНФЕКЦИИBordinD. SБординД. С

MD, Head of the Department of Pathology of the Pancreas, Biliary Tract and Upper Digestive Tract; Professor at the Department of General Medical Practice (Family Medicine)

д.м.н., зав. отделом патологии поджелудочной железы, желчных путей и верхних отделов пищеварительного тракта; проф. кафедры общеврачебной практики (семейной медицины)

d.bordin@mknc.ruEmbutnieksYu. VЭмбутниексЮ. ВVoynovanI. NВойнованИ. НKolbasnikovS. VКолбасниковС. ВSBHCI “Moscow Clinical Research and Practical Center" of Moscow Healthcare DepartmentГБУЗ «Московский клинический научно-практический центр» ДЗ г. МосквыFAPE SBEIHPE “Tver State Medical Academy" of RMHФПДО ГБОУ ВПО «Тверской государственный медицинский университет» МЗ России20032017246NO6 (2017)№6 (2017)656926022023Copyright ©; 2017, Bionika MediaCopyright ©; 2017, ООО «Бионика Медиа»2017Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/289827

Helicobacter pylori (HP) infection is one of the most common human infections, which leads to the development of chronic gastritis, gastric and duodenal ulcers, MALT-lymphoma and gastric adenocarcinoma. Increased HP resistance to previously effective schemes of eradication therapy is a source of serious concern, and requires improvement of therapeutic strategies. The literature review shows that some probiotic strains have an inhibitory effect on the HP, and their use is recommended as an addition to the standard eradication therapy that can reduce side effects and increase its effectiveness.

Helicobacter pylori (HP) - одна из наиболее часто встречаемых инфекций человека, которая приводит к развитию хронического гастрита, язвенной болезни желудка и двенадцатиперстной кишки, MALT-лимфомы и аденокарциномы желудка. Рост устойчивости HP к ранее эффективным схемам эрадикационной терапии вызывает серьезную озабоченность и требует усовершенствования терапевтических стратегий. Обзор литературы демонстрирует, что некоторые пробиотические штаммы оказывают ингибирующее влияние на HP и рекомендуются как дополнение к стандартной эрадикационной терапии, способное уменьшать побочные эффекты и повышать ее эффективность.

Helicobacter pyloriHelicobacter pylorieradication therapyprobioticsэрадикационная терапияпробиотикиMalfertheiner P., Megraud F., O'Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., Bazzoli F., Gasbarrini A., Atherton J., Graham D.Y., Hunt R., Moayyedi P., Rokkas T., Rugge M., Selgrad M., Suerbaum S., Sugano K., El-Omar E.M; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30.Sugano K., Tack J., Kuipers E.J., Graham D.Y., El-Omar E.M., Miura S., Haruma K., Asaka M., Uemura N., Malfertheiner P; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-67.Panpetch W., Spinler J.K., Versalovic J., Tumwasorn S. Characterization of Lactobacillus salivarius strains B37 and B60 capable of inhibiting iL-8 production in Helicobacter pylori-stimulated gastric epithelial cells. BMC. Microbiol. 2016;16(1):242.Bartchewsky W.Jr., Martini M.R., Masiero M., Squassoni A.C., Alvarez M.C., Ladeira M.S., Salvatore D., Trevisan M., Pedrazzoli J.Jr., Ribeiro M.L. Effect of Helicobacter pylori infection on iL-8, iL-1beta and COX-2 expression in patients with chronic gastritis and gastric cancer. Scand. J. Gastroenterol. 2009;44(2):153-61.Yamada S., Kato S., Matsuhisa T., Makonkawkeyoon L., Yoshida M., Chakrabandhu T., Lertprasertsuk N., Suttharat P., Chakrabandhu B., Nishiumi S., et al. Predominant mucosal iL-8 mRNA expression in non-cagA Thais is risk for gastric cancer. World J. Gastroenterol. 2013;19:2941-49.Atherton J.C., Tham K.T., Peek Jr.R.M., Cover T.L., Blaser M.J. Density of Helicobacter pylori infection in vivo as assessed by quantitative culture and histology. JiD. 1996;174:552-56.Stolte M., Stadelmann O., Bethke B., Burkard G. Relationships between the degree of Helicobacter pylori colonisation and the degree and activity of gastritis, surface epithelial degeneration and mucus secretion. Z. Gastroenterol. 1995;33:89-93.Graham D.Y., Fischbach L. Helicobacter pylori infection. N. Engl. J. Med. 2010;363(6):595-96.Sgouras D.N., Trang T.T., Yamaoka Y. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2015;20(Suppl. 1):8-16.Alm R.A., Ling L.-S.L., Moir D.T., et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature. 1999;397(6715):176-80.Tomb J.F., White O., Kerlavage A.R., et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. 1997;388(6642):539-47.Lu H., Yamaoka Y., Graham D.Y. Helicobacter pylori virulence factors: facts and fantasies. Curr. Opin. Gastroenterol. 2005;21:653-59.Delahay R., Rugge M. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2012;17(Suppl. 1):9-15.Sakaki N., Kozawa H., Egawa N., Tu Y., Sanaka M. Ten-year prospective follow-up study on the relationship between Helicobacter pylori infection and progression of atrophic gastritis, particularly assessed by endoscopic findings. Aliment Pharmacol Ther. 2002;16(Suppl. 2):198-203.Correa P. Helicobacter pylori and gastric carcinogenesis. Am. J. Surg. Pathol. 1995;19(Suppl. 1):37-43.Takahashi S., Igarashi H., Masubuchi N., et al. Helicobacter pylori and the development of atrophic gastritis. Nippon. Rinsho. 1993;51(12):3231-35.Correa P. The biological model of gastric carcinogenesis. iARC. Sci. Publ. 2004;157:301-10.Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested with prospective cohorts. Gut. 2001;49:347-53.Malfertheiner P., Megraud F., O'Morain C.A., et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut. 2012;61:646-64.Mégraud F. Failed Eradication for Helicobacter pylori. What Should Be Done? Dig. Dis. 2016; 34(5):505-9.Thung I., Aramin H., Vavinskaya V., et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment. Pharmacol. Ther. 2016;43:514-33.Talebi Bezmin Abadi A. Vaccine against Helicobacter pylori: inevitable approach. World J. Gastroenterol. 2016;22(11):3150-57.Delgado S., Leite A.M., Ruas-Madiedo P., Mayo B. Probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis. Front. Microbiol. 2015;5:766.Fallone C.A., Chiba N., van Zanten S.V., Fischbach L., Gisbert J.P., Hunt R.H., Jones N.L., Render C., Leontiadis G.I., Moayyedi P., Marshall J.K. The Toronto Consensus for the Treatment of Helicobacter pylori infection in Adults. Gastroenterology. 2016;151(1):51-69.Sherman L.A., Savage D.C. Lipoteichoic acids in Lactobacillus strains that colonize the mouse gastric epithelium. Appl. Environ. Microbiol. 1986;52:302-4.Valeur N., Engel P., Carbajal N., Connolly E., Ladefoged K. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl. Environ. Microbiol. 2004;70:1176-81.Ruggiero P. Use of probiotics in the fight against Helicobacter pylori. World J. Gastrointest. Pathophysiol. 2014;5:384-91.Homan M., Orel R. Are probiotics useful in Helicobacter pylori eradication? World J. Gastroenterol. 2015;21:10644-53.Lee J.S., Paek N.S., Kwon O.S., Hahm K.B. Antiinflammatory actions of probiotics through activating suppressor of cytokine signaling (SOCS) expression and signaling in Helicobacter pylori infection: a novel mechanism. J. Gastroenterol Hepatol. 2010;25:194-202.Borruel N., Casellas F., Antolin M., Llopis M., Carol M., Esplin E., Naval J., Guarner F., Malagelada J.R. Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa. Am. J. Gastroenterol. 2003;98:865-70.Lesbros-Pantoflickova D., Corthésy-Theulaz I., Blum A.L. Helicobacter pylori and probiotics. J. Nutr. 2007;137:812S-8S.Francavilla R., Lionetti E., Castellaneta S.P., Magistà A.M., Maurogiovanni G., Bucci N., De Canio A., Indrio F., Cavallo L., Ierardi E., Miniello V.L. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter. 2008;13:127-34.Schaefer L., Auchtung T.A., Hermans K.E., Whitehead D., Borhan B., Britton R.A. The antimicrobial compound reuterin(3-hydroxypropionaldehyde) induces oxidative stress via interaction withthiol groups. Microbiology. 2010;156(Pt. 6):1589-99.Byrd J.C., Yunker C.K., Xu Q.S., Sternberg L.R., Bresalier R.S. inhibition of gastric mucin synthesis by Helicobacter pylori. Gastroenterology. 2000;118:1072-79.Mack D.R., Ahrne S., Hyde L., Wei S., Hollingsworth M.A. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut. 2003;52:827-33.Mukai T., Asasaka T., Sato E., Mori K., Matsumoto M., Ohori H. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS immunol. Med. Microbiol. 2002;32:105-10.Molin G., Jeppsson B., Johansson M.-L., et al. Numerical taxonomy of Lactobacillus spp. associated to healthy and diseased mucosa of the human intestines. J. Appl. Microbiol. 1993;74:314-23.Saulnier D.M., Santos F., Roos S., Mistretta T.A., Spinler J.K., Molenaar D., Teusink B., Versalovic J. Exploring metabolic pathway reconstruction and genome-wide expression profiling in Lactobacillus reuteri to define functional probiotic features. PLoS One. 2011;6(4):e18783.Mehling H., Busjahn A. Non-Viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a New Approach to Helicobacter pylori Control in Humans. Nutrients. 2013;5:3062-73.Holz C., Busjahn A., Mehling H., Arya S., Boettner M., Habibi H., Lang C. Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study. Probiotics Antimicrob. Proteins. 2015;7(2):91-100.Бордин Д.С., Войнован И.Н., Хомерики С.Г., Янова О.Б., Ким В.А., Быстровская Е.В., Шишин К.В. Эффективность и безопасность Lactobacillus reuteri DSMZ17648 у инфицированных Helicobacter pylori. Лечащий врач. 2016;5:106-10.Emara M.H., Mohamed S.Y., Abdel-Aziz H.R. Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial. Ther. Adv. Gastroenterol. 2014;7(1):4-13.Francavilla R., Lionetti E., Castellaneta S.P., Magistà A.M., Maurogiovanni G., Bucci N., De Canio A., indrio F., Cavallo L., Ierardi E., Miniello V.L. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter. 2008;13(2):127-34.Efrati C., Nicolini G., Cannaviello C., O'Sed N.P., Valabrega S. Helicobacter pylori eradication: sequential therapy and Lactobacillus reuteri supplementation. World J. Gastroenterol. 2012;18(43):6250-54.Francavilla R., Polimeno L., Demichina A., Maurogiovanni G., Principi B., Scaccianoce G., Ierardi E., Russo F., Riezzo G., Di Leo A., Cavallo L., Francavilla A.,Versalovic J. Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebocontrolled study. J. Clin. Gastroenterol. 2014; 48(5):407-13.Ojetti V., Bruno G., Ainora M.E., Gigante G., Rizzo G., Roccarina D., Gasbarrini A. impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy. Gastroenterol. Res. Pract. 2012;2012:740381.